ABC | Volume 114, Nº5, Maio 2020

Posicionamento Posicionamento da Sociedade Brasileira de Cardiologia para Gravidez e Planejamento Familiar na Mulher Portadora de Cardiopatia – 2020 Arq Bras Cardiol. 2020; 114(5):849-942 51. Canobbio MM, Warnes CA, Aboulhosn J, Connolly HM, Khanna A, Koos BJ. Management of Pregnancy in PatientsWith Complex Congenital Heart Disease. A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2017;135(8):e50-87. 52. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom- Lundqvist C, Cifkova R, De Bonis M, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-241. 53. Pariente G, Leibson T, Carls A, Adams. Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016;13(11):e1002160. 54. Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015;39(7):512-9. 55. Parry E, Shields R, Turnbull AC. Transit time in the small intestine in pregnancy. J Obstet Gynaecol Br Commonw. 1970;77(10):900-1. 56. CarterBL,GarnettWR,PellockJM,StrattonMA,HowellJR.Effectofantacids on phenytoin bioavailability. Ther Drug Monit. 1981;3(4):333-40. 57. Anger GJ, Piquette-MillerM. Pharmacokinetic studies in pregnant women. Clin Pharmacol Ther. 2008;83(1):184–7. 58. Tracy TS, Venkataramanan R, Glover DD, Caritis SN; National Institute for Child Health and Human Development Network of Maternal- Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 andCYP3AActivity) during pregnancy. Am J Obs Gynecol. 2005; 192(2):633-9. 59. Davison JM,DunlopW.Renalhemodynamicsandtubular functionnormal human pregnancy. Kidney Int. 1980;18(2):152-61. 60. Davison JM, Noble MC. Serial changes in 24 hour creatinine clearance during normal menstrual cycles and the first trimester of pregnancy. Br J Obstet Gynaecol. 1981;88(1):10-7. 61. Cheung KL, Lafayette RA. Renal physiology of pregnancy. Adv Chronic Kidney Dis. 2013; 20(3):209-14. 62. U. S. Food and Drug Administration. Milestones in U. S. Food and Drug Law History. 2018. [Internet]. [Cited in 2019 Feb 11]. Available from:// www.fda.gov//about-fda/fdas-evolving-regulatory-powers/milestones-us- food-and-drug-law-history 63. Brucker MC, King TL. The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule. J Midwifery Womens Health. 2017;62(3):308-16. 64. Clark SM, DunnHE, Hankins GD. A reviewof oral labetalol and nifedipine in mild to moderate hypertension in pregnancy. Semin Perinatol. 2015;39(7):548-55. 65. van Vliet EO, Schuit E, Heida KY, Opmeer BC, Kok M, Gyselaers W, et al. Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial). BMC Pregnancy Childbirth. 2014 Mar;14:93. 66. Bateman BT, Hernandez-Diaz S, Huybrechts KF, Palmsten K, Mogun H, Ecker JL, et al. Outpatient calcium–channel blockers and the risk of postpartumhaemorrhage: a cohort study. BJOG. 2013;120(13):1668-76; dicussion 1676-7. 67. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1(8273):647-9. 68. Slim R, Ben Salem C, Hmouda H, Bouraoui K. Hepatotoxicity of alpha- methyldopa in pregnancy. J Clin Pharm Ther. 2010;35(3):361-3. 69. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta- analysis. BMJ. 2003;327(7421):955-60. 70. Buchanan ML, Easterling TR, Carr DB, Shen DD, Risler LJ, Nelson WL, et al. Clonidine pharmacokinetics in pregnancy. Drug Metab Dispos. 2009;37(4):702-5. 71. ACOGPractice Bulletin nº 203:Chronic Hypertension in Pregnancy. Obst Gynecol. 2019 Jan;133(1): e26-e50 72. Bowen ME, Ray WA, Arbogast PG, Ding H, Cooper WO. Increasing exposure to angiotensinconverting enzyme inhibitors in pregnancy. Am J Obstet Gynecol. 2008;198(3):291.e1-5. 73. Halpern D G, Weinberg C R, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM. Use of Medication for Cardivascular Disease During Pregnancy. J Am Coll Cardiol. 2019;73(4):457-76. 74. Elkayam U, Goodwin TM. Adenosine therapy for supraventricular tachycardia during pregnancy. Am J Cardiol. 1995;75(7):521-3. 75. Matsubara S, Kuwata T, Mitsuhashi T. Adenosine for maternal supraventricular tachycardia and preterm delivery. J Obstet Gynaecol Can. 2011;33(8):794-5. 76. Bateman BT, Patorno E, Desai RJ, Seely EW, MogunH, Maeda A, et al. Late pregnancy beta blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics. 2016;138(3). pii: e20160731. 77. Petersen KM, Jimenez-Solem E, Andersen JT, Petersen M, Brødbæk K, Køber L, et al. β -Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012;2(4):e001185. 78. Ersboll AS, Hedegaard M, Sondergaard L, Ersboll M, Johansen M. Treatment with oral betablockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction. BJOG. 2014; 121(5):618-26. 79. Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnanciescomplicatedbyhypertension.AmJHypertens.1999;12(6):541-7. 80. LipGY, BeeversM, Churchill D, Shaffer LM, Beevers DG. Effect of atenolol on birth weight. Am J Cardiol. 1997;79(10):1436-8. 81. Pruyn SC, Phelan JP, Buchanan GC. Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol. 1979;135(4):485-9. 82. Ryu RJ, Eyal S, Easterling TR, Caritis SN, Venkataraman R, Hankins G, et al. Pharmacokinetics of metoprolol during pregnancy and lactation. J Clin Pharmacol. 2016;56(5):581-9. 83. HögstedtS,RaneA.Plasmaconcentration-effectrelationshipofmetoprolol during and after pregnancy. Eur J Clin Pharmacol. 1993;44(3):243-6. 84. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984;9(2):136-56. 85. Lomenick JP, JacksonWA, BackeljauwPF. Amiodarone-induced neonatal hypothyroidism: a unique formof transient early-onset hypothyroidism. J Perinatol. 2004;24(6):397-9. 86. Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest. 2001;24(2):116-30. 87. Capone CA, Gebb J, Dar P, Shenoy RU. Favorable neurodevelopmental outcome in a hypothyroid neonate following intracordal amiodarone for cardioversion of refractory supraventricular tachycardia in a fetus. J Neonatal Perinatal Med. 2014;7(4):305-9. 88. Mitani GM, Steinberg I, Lien EJ, Harrison EC, Elkayam U. The harmacokinetics of antiarrhythmic agents in pregnancy and lactation. Clin Pharmacokinet. 1987;12(4):253-91. 89. Allen NM, Page RL. Procainamide administration during pregnancy. Clin Pharm. 1993;12(1):58-60. 90. Tanaka K, Tanaka H, Kamiya C, Katsuragi S, Sawada M, Tsuritani M, et al. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J. 2016;80(10):2221-6. 91. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta- analysis of individual patient data. Lancet. 2007;369(9575):1791-8. 932